A few months ago, the EMA (European Medicines Agency) carried out a re-evaluation of medicinal products containing bufexamac. This component is a nonsteroidal anti-inflammatory drug recommended in the symptomatic treatment of pruritus (itching).
Following this study, this agency “concluded that a benefit / risk ratio is now unfavorable for drugs containing bufexamac due to the high risk of sometimes serious contact allergy” explains a press release from AFSSAPS (French Security Agency). Sanitary of Health Products) today.
Indeed, it would have been observed many allergies contact with the product requiring hospitalization. Eczema remains the most observed side effect.
As a result, the European Commission requested the withdrawal brand new releases of drugs containing bufexamac. In France, the only drug concerned is cream “Parfenac 5%“from the Wyeth Family Health lab.
Thus, Parfenac® will no longer be available from September 14, 2010 and Afssaps “recommends that patients currently treated with Parfenac® stop their treatment and consult their doctor so that he can reconsider their treatment, or take advice from their pharmacist “.
More info on www.afssaps.fr
